AngioDynamics (ANGO) last issued guidance on April 2, 2026 for fiscal year 2026. The company guided earnings per share in the range of $-0.30 - $-0.23, compared to a consensus EPS estimate of $-0.28. AngioDynamics also guided revenue in the range of $313.50M - $315.50M for the period.
Compared to prior guidance, AngioDynamics raised its EPS outlook from a previous range of $-0.33 - $-0.23. On the revenue side, the company maintained its revenue forecast from a prior range of $312.00M - $314.00M.
AngioDynamics has issued 18 guidance updates between July 12, 2022 and April 2, 2026. During this period, the company raised its outlook 6 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
Review all historical guidance issued by AngioDynamics, including EPS and revenue forecasts across quarterly and annual periods.
The most recent guidance for AngioDynamics (ANGO) was reported on April 2, 2026 for the fiscal year 2026. The company provided earnings per share guidance in the range of $-0.30 to $-0.23, compared to the estimated EPS of $-0.28. Additionally, AngioDynamics forecasted revenue between $313.50M and $315.50M for the period.
AngioDynamics (ANGO) guided EPS in the range of $-0.30 to $-0.23 for the fiscal year 2026. The consensus analyst EPS estimate is $-0.28.
AngioDynamics (ANGO) guided revenue in the range of $313.50M to $315.50M for the fiscal year 2026.
AngioDynamics (ANGO) raised its EPS guidance from a prior range of $-0.33 - $-0.23 to $-0.30 - $-0.23 for the fiscal year 2026.
AngioDynamics (ANGO) last issued guidance on April 2, 2026 for the fiscal year 2026.